Tech Company Financing Transactions

Potentia Pharmaceuticals Funding Round

Potentia Pharmaceuticals, based in Louisville, secured $12 million from HealthCare Ventures, MASA Life Science Ventures and private investors.

Transaction Overview

Company Name
Potentia Pharmaceuticals
Announced On
4/9/2008
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Series B
Investors

HealthCare Ventures (Lead Investor) (Douglas Onsi)

MASA Life Science Ventures (Lead Investor) (Sinclair Dunlop)

Proceeds Purpose
The funds will allow Potentia to complete Phase I and move into Phase II clinical development of Potentia's novel investigational drug candidate, POT-4. POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD).

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
201 E. Jefferson Street 312
Louisville, KY 40202
USA
Phone
(502) 569-1053
Website
www.potentiapharma.com
Email Address
[email protected]
Overview
Potentia Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the eye such as age-related macular degeneration.
Profile
Potentia Pharmaceuticals LinkedIn Company Profile
Social Media
Potentia Pharmaceuticals Company Twitter Account
Company News
Potentia Pharmaceuticals News
Facebook
Potentia Pharmaceuticals on Facebook
YouTube
Potentia Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Cedric Francois
  Cedric Francois LinkedIn Profile  Cedric Francois Twitter Account  Cedric Francois News  Cedric Francois on Facebook
Chief Medical Officer
Jason Slakter
  Jason Slakter LinkedIn Profile  Jason Slakter Twitter Account  Jason Slakter News  Jason Slakter on Facebook
Chief Operating Officer
Pascal Deschatelets
  Pascal Deschatelets LinkedIn Profile  Pascal Deschatelets Twitter Account  Pascal Deschatelets News  Pascal Deschatelets on Facebook
Chief Scientific Officer
Paul Olson
  Paul Olson LinkedIn Profile  Paul Olson Twitter Account  Paul Olson News  Paul Olson on Facebook
VP - General Counsel
Monica Gerber
  Monica Gerber LinkedIn Profile  Monica Gerber Twitter Account  Monica Gerber News  Monica Gerber on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/8/2008: ArtusLabs venture capital transaction
Next: 4/9/2008: Storwize venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.